Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data

Background The recommendation for postoperative chemotherapy in pancreatic ductal adenocarcinoma (PDAC) is based on prospective randomized trials. However, patients included in clinical trials do not often reflect the overall patient population treated in clinical practice.